Fosamax and Osteonecrosis of the Jaw: Understanding Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of Health Information and the Shift to Specialized Risk Awareness

The legacy of general health and science information dissemination has long provided a foundational framework for public understanding of medical risks and therapeutic benefits. Within this broad context, the communication of drug safety profiles has evolved from simple advisories to nuanced discussions of adverse event associations. This heritage established the expectation that health information should be accessible, evidence-informed, and contextualized within real-world patient experiences. As the scope of health communication expanded, it became necessary to address not only common side effects but also rare, serious conditions linked to specific pharmaceutical exposures. The transition from general health literacy to specialized risk awareness is exemplified by the growing attention to bisphosphonate therapies, such as Fosamax, and their potential relationship with osteonecrosis of the jaw. This pivot reflects a shift from population-level health guidance toward individualized risk assessment, particularly in clinical settings where long-term medication use intersects with dental health. The occupational exposure concern emerges when considering healthcare professionals, dental practitioners, and patients who must navigate the implications of prolonged Fosamax use. Understanding the causation of osteonecrosis of the jaw in this context requires a careful examination of exposure duration, dosage, and patient susceptibility factors, moving beyond general health narratives to address specific, practice-relevant risks. This transition underscores the need for targeted communication strategies that bridge broad health science principles with precise, actionable information for those directly involved in treatment decisions.

Bridging General Health Science to Fosamax-Specific Risks

Building on the legacy of health communication, this section transitions to the specific medical literature on Fosamax (alendronate) and its association with osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed necrotic bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and non-healing extraction sockets. Diagnosis is based on clinical examination and imaging, with a focus on identifying exposed bone persisting for more than eight weeks in the absence of prior radiation therapy.

Mechanisms and Risk Factors for Fosamax-Associated ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are thought to involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. This suppression can impair the jawbone's ability to remodel and repair microdamage, particularly after invasive dental procedures. A multiscale characterization of jawbone has provided comprehensive information to help understand jawbone-specific responses to bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under Section 5.4, stating that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It notes that the risk of ONJ may increase with duration of exposure to bisphosphonates and that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that the optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use should be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). These warnings provide guidance to clinicians and patients, but the rare nature of ONJ may lead to underrecognition.

Causation Evidence: Temporal Relationship and Epidemiological Data

Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as bone pain were similar in the Fosamax and placebo groups, but ONJ specifically has been reported in patients taking bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal link, as rechallenge can reproduce the adverse effect. The timeline between exposure and documented harm is variable. A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that longer exposure increases risk, but the absolute risk is small. For affected patients, establishing causation requires documenting the duration of Fosamax use, the presence of risk factors such as dental procedures, and the exclusion of other causes like cancer or radiation therapy. The label emphasizes that ONJ can occur spontaneously but is generally associated with dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Therefore, a patient who develops ONJ after prolonged Fosamax use and a tooth extraction may have a stronger causation argument than one with spontaneous onset and short-term use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication approved for treating and preventing osteoporosis, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget's disease of bone. It works by inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

ONJ is a condition characterized by exposed necrotic bone in the jaw, often associated with tooth extraction or local infection with delayed healing. Fosamax can suppress bone turnover by inhibiting osteoclast activity, impairing the jawbone's ability to repair microdamage, especially after dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How does the duration of Fosamax use affect ONJ risk?

A cohort study found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use. Absolute risks are low (about 0.05% after 5 years) and diminish after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.